The Current Situation and Development Prospect of Whole-Genome Screening

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jan 11

PMID 38203828

Authors

Caiting Yang

Yu Lei

Tinglin Ren

Mingze Yao

Affiliations

Soon will be listed here.

Abstract

High-throughput genetic screening is useful for discovering critical genes or gene sequences that trigger specific cell functions and/or phenotypes. Loss-of-function genetic screening is mainly achieved through RNA interference (RNAi), CRISPR knock-out (CRISPRko), and CRISPR interference (CRISPRi) technologies. Gain-of-function genetic screening mainly depends on the overexpression of a cDNA library and CRISPR activation (CRISPRa). Base editing can perform both gain- and loss-of-function genetic screening. This review discusses genetic screening techniques based on Cas9 nuclease, including Cas9-mediated genome knock-out and dCas9-based gene activation and interference. We compare these methods with previous genetic screening techniques based on RNAi and cDNA library overexpression and propose future prospects and applications for CRISPR screening.

Citing Articles

Identification of host factors for livestock and poultry viruses: genome-wide screening technology based on the CRISPR system.

Hu S, Gan M, Wei Z, Shang P, Song L, Feng J Front Microbiol. 2024; 15:1498641.

PMID: 39640855 PMC: 11619636. DOI: 10.3389/fmicb.2024.1498641.

A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer.

Kawai Y, Nagayama A, Miyao K, Takeuchi M, Yokoe T, Kameyama T Breast Cancer. 2024; 32(1):120-131.

PMID: 39352623 DOI: 10.1007/s12282-024-01641-y.

References

Bhaya D, Davison M, Barrangou R . CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet. 2011; 45:273-97. DOI: 10.1146/annurev-genet-110410-132430. View

Cuella-Martin R, Hayward S, Fan X, Chen X, Huang J, Taglialatela A . Functional interrogation of DNA damage response variants with base editing screens. Cell. 2021; 184(4):1081-1097.e19. PMC: 8018281. DOI: 10.1016/j.cell.2021.01.041. View

La Russa M, Qi L . The New State of the Art: Cas9 for Gene Activation and Repression. Mol Cell Biol. 2015; 35(22):3800-9. PMC: 4609748. DOI: 10.1128/MCB.00512-15. View

Huang C, Li G, Wu J, Liang J, Wang X . Identification of pathogenic variants in cancer genes using base editing screens with editing efficiency correction. Genome Biol. 2021; 22(1):80. PMC: 7945310. DOI: 10.1186/s13059-021-02305-2. View

Johnson L, Zhang D, Zhou K, Lee S, Liu S, Dilliard S . Lipid Nanoparticle (LNP) Chemistry Can Endow Unique RNA Delivery Fates within the Liver That Alter Therapeutic Outcomes in a Cancer Model. Mol Pharm. 2022; 19(11):3973-3986. PMC: 9888001. DOI: 10.1021/acs.molpharmaceut.2c00442. View

Onuma H, Sato Y, Harashima H . Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing. J Control Release. 2023; 355:406-416. DOI: 10.1016/j.jconrel.2023.02.008. View

Xu P, Liu Z, Liu Y, Ma H, Xu Y, Bao Y . Genome-wide interrogation of gene functions through base editor screens empowered by barcoded sgRNAs. Nat Biotechnol. 2021; 39(11):1403-1413. DOI: 10.1038/s41587-021-00944-1. View

Chavez A, Scheiman J, Vora S, Pruitt B, Tuttle M, Iyer E . Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015; 12(4):326-8. PMC: 4393883. DOI: 10.1038/nmeth.3312. View

Replogle J, Saunders R, Pogson A, Hussmann J, Lenail A, Guna A . Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell. 2022; 185(14):2559-2575.e28. PMC: 9380471. DOI: 10.1016/j.cell.2022.05.013. View

10.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

11.

Rosenbluh J, Xu H, Harrington W, Gill S, Wang X, Vazquez F . Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun. 2017; 8:15403. PMC: 5457492. DOI: 10.1038/ncomms15403. View

12.

Dhainaut M, Rose S, Akturk G, Wroblewska A, Nielsen S, Park E . Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022; 185(7):1223-1239.e20. PMC: 8992964. DOI: 10.1016/j.cell.2022.02.015. View

13.

Pierce S, Granja J, Greenleaf W . High-throughput single-cell chromatin accessibility CRISPR screens enable unbiased identification of regulatory networks in cancer. Nat Commun. 2021; 12(1):2969. PMC: 8137922. DOI: 10.1038/s41467-021-23213-w. View

14.

Datlinger P, Rendeiro A, Schmidl C, Krausgruber T, Traxler P, Klughammer J . Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017; 14(3):297-301. PMC: 5334791. DOI: 10.1038/nmeth.4177. View

15.

Zemaitis K, Subramaniam A, Galeev R, Prosz A, Jassinskaja M, Hansson J . RNAi Screen Identifies MTA1 as an Epigenetic Modifier of Differentiation Commitment in Human HSPCs. Exp Hematol. 2022; 115:20-29. DOI: 10.1016/j.exphem.2022.08.004. View

16.

Yue H, Zhou X, Cheng M, Xing D . Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing. Nanoscale. 2017; 10(3):1063-1071. DOI: 10.1039/c7nr07999k. View

17.

Liang Y, Zhang J, Xu C, Wang J, Han W, Yang J . Biomimetic Mineralized CRISPR/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing. ACS Nano. 2023; 17(15):15025-15043. DOI: 10.1021/acsnano.3c04116. View

18.

Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View

19.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

20.

Ravichandran M, Maddalo D . Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling. Front Genet. 2023; 14:1273994. PMC: 10613999. DOI: 10.3389/fgene.2023.1273994. View